Guggenheim Reiterates Buy on Endo Int'l (ENDP) Following Updated Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/3/2026

1. AMZN
2. RBLX
3. AAPL
4. COIN
5. RDDT
6. NBIX
7. DXCM
8. GDDY
9. KKR
10. WU

Go back to Guggenheim Reiterates Buy on Endo Int'l (ENDP) Following Updated Guidance

Endo Completes Acquisition of Par Pharmaceutical and Provides Financial Guidance

September 28, 2015 6:30 AM EDT

-  Par Acquisition Enhances Endo's Position as a Leading Global Specialty Pharmaceutical Company with One of Industry's Fastest Growing Generics Businesses and Establishes Powerful Platform for Future Growth and Strategic M&A

-  Combined U.S. Generics Business Unit to be Named Par Pharmaceutical, an Endo International Company

-  Updated 2015 Full Year Financial Guidance to $3.22 to $3.27 Billion in Revenues; Endo Maintains Upper End of 2015 Adjusted Diluted EPS from Continuing Operations Guidance of $4.50 to $4.60

- 2016 Adjusted Diluted EPS from Continuing Operations Expected to be in the Range of... More

Endo Announces Termination Of HSR Act Waiting Period In Connection With Its Proposed Acquisition Of Par Pharmaceutical

September 25, 2015 6:00 AM EDT

DUBLIN, Sept. 25, 2015 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that on September 24, 2015, it received notice of termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, from the U.S. Federal Trade Commission in connection with Endo's previously... More